These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37536222)
1. A meta analysis on the utility of Anakinra in severe COVID-19 disease. Mohamed Hussein AAR; Sayad R; Abdelshafi A; Hammam IA; Kedwany AM; Elkholy SA; Ibrahim IH Cytokine; 2023 Sep; 169():156311. PubMed ID: 37536222 [TBL] [Abstract][Full Text] [Related]
2. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial. Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B; JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155 [TBL] [Abstract][Full Text] [Related]
5. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial. Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441 [TBL] [Abstract][Full Text] [Related]
6. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354 [TBL] [Abstract][Full Text] [Related]
7. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Pasin L; Cavalli G; Navalesi P; Sella N; Landoni G; Yavorovskiy AG; Likhvantsev VV; Zangrillo A; Dagna L; Monti G Eur J Intern Med; 2021 Apr; 86():34-40. PubMed ID: 33581979 [TBL] [Abstract][Full Text] [Related]
8. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. CORIMUNO-19 Collaborative group Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450 [TBL] [Abstract][Full Text] [Related]
9. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm. Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812 [TBL] [Abstract][Full Text] [Related]
10. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576 [TBL] [Abstract][Full Text] [Related]
11. Current evidence on the use of anakinra in COVID-19. Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562 [TBL] [Abstract][Full Text] [Related]
12. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817 [TBL] [Abstract][Full Text] [Related]
13. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. Barkas F; Filippas-Ntekouan S; Kosmidou M; Liberopoulos E; Liontos A; Milionis H Rheumatology (Oxford); 2021 Dec; 60(12):5527-5537. PubMed ID: 33999135 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis. Malık H; Bınt Abdul Jabbar H; Latıf F; Sarfraz A; Sarfraz Z; Sarfraz M Turk J Med Sci; 2022 Jun; 52(3):547-553. PubMed ID: 36326309 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
16. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis. Udomsinprasert W; Jittikoon J; Sangroongruangsri S; Chaikledkaew U J Clin Immunol; 2021 Jan; 41(1):11-22. PubMed ID: 33128665 [TBL] [Abstract][Full Text] [Related]
17. An open label trial of anakinra to prevent respiratory failure in COVID-19. Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ Elife; 2021 Mar; 10():. PubMed ID: 33682678 [TBL] [Abstract][Full Text] [Related]
18. Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Shang W; Zhang Y; Wang G; Han D Rev Med Virol; 2023 Mar; 33(2):e2418. PubMed ID: 36600551 [TBL] [Abstract][Full Text] [Related]
19. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Kharazmi AB; Moradi O; Haghighi M; Kouchek M; Manafi-Rasi A; Raoufi M; Shoaei SD; Hadavand F; Nabavi M; Miri MM; Salarian S; Shojaei S; Khalili S; Sistanizad M; Sadeghi S; Karagah A; Asgari S; Jaffaraghaei M; Araghi S Immun Inflamm Dis; 2022 Feb; 10(2):201-208. PubMed ID: 34762351 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]